Glaukos(NYSE) GKOS

Glaukos Corporation makes tiny devices and drugs to treat eye diseases. These products help people who suffer from glaucoma or vision loss. They replace daily eye drops with long-lasting treatments.

Pills, Stents, and Vision Tools

• Glaucoma Therapies: Micro-bypass stents and drug implants designed to lower eye pressure; represented $118.5 million in United States net sales for the three-month period ended June 30, 2026.
• Corneal Health: Pharmaceutical treatments and systems used for rare eye disorders; generated $30.4 million in net sales for the three-month period ended June 30, 2026.
• International Sales: Global distribution of eye treatments; contributed $36.6 million in net sales for the three-month period ended June 30, 2026.

Scaling Up and New Approvals

• Launched iDose TR in 2024 to provide long-acting drug therapy for glaucoma, a disease that increases eye pressure.
• Received FDA approval for Epioxa in 2025 as an incision-free treatment for keratoconus, a rare corneal disorder.
• Acquired Mobius Therapeutics in May 2025 to expand the pharmaceutical product portfolio.
• Planned a new manufacturing facility in Alabama that involves over $80 million in capital expenditures.

Pioneering Better Eye Care

Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to traditional surgery or daily eye drops. The company manages its own sales teams in the United States while using distributors in certain international markets.

A Look at the Numbers

• Net sales reached $336.2 million for the six-month period ended June 30, 2026, up 46% year over year.
• Gross margin reached 82% for the three-month period ended June 30, 2026, up from 78% year over year.
• Recorded a net loss of $38.2 million for the six-month period ended June 30, 2026.
• Maintained cash and short-term investments totaling $286.2 million as of June 30, 2026.

Bottom Line

Glaukos has transitioned from a medical device maker into a hybrid pharmaceutical and technology firm. Its focus on long-acting therapies reduces the daily treatment burden for patients with chronic eye conditions.